Starting Semaglutide in 2026: Approved vs Compounded, Pharmacy Checks, and Follow-Up Questions

September 1, 2026Atlanta Medical Institute

Atlanta adults considering semaglutide can use this guide to distinguish FDA‑approved products from compounded versions, check pharmacy legitimacy, and plan physician‑led follow‑up without making medication changes on their own.

Atlanta Medical Institute | Dated 2026-09-01 For Atlanta adults exploring clinician-supervised GLP-1 care, semaglutide raises practical questions: How do you tell an FDA-approved product from a compounded alternative, how can you assess pharmacy legitimacy, and which monitoring and follow-up topics should be clarified with your supervising physician before you begin? This article organizes current evidence and regulatory points so you can ask precise questions without making medication changes on your own.

Semaglutide in 2026: What to know about FDA‑approved vs compounded

FDA-approved semaglutide products have undergone FDA review for quality, safety, and effectiveness; they come with FDA-approved labeling, including a Medication Guide that outlines important risks, storage, and use information [8]. Compounded semaglutide is made by a pharmacy or outsourcing facility for an individual patient or office use under federal compounding provisions and does not undergo FDA approval. FDA has outlined concerns with unapproved GLP‑1 drugs used for weight management, including quality, potency, and labeling differences, and urges caution with unapproved versions [4]. The American Diabetes Association advises using FDA‑approved GLP‑1 receptor agonists when possible and exercising caution with compounded alternatives [5].

As national GLP‑1 supply has moved toward stabilization, FDA clarified how compounding policies apply and how enforcement discretion may evolve as shortages resolve. When an FDA-approved version is not in shortage, federal law generally restricts compounding copies of commercially available drugs; as availability improves, FDA indicates that 503A and 503B compounders are subject to longstanding limits on producing copies outside narrow allowances [1].

How to tell whether a product is FDA‑approved or compounded

Before filling a prescription, you can ask targeted questions that distinguish FDA‑approved products from compounded alternatives. These questions do not substitute for clinician guidance and do not recommend any medication changes without the prescribing clinician.

Ask for the exact product name as it will appear on the label and whether it is an FDA‑approved brand or a compounded preparation. FDA‑approved semaglutide products include an FDA Medication Guide; pharmacies dispensing approved products should provide it with the medication [8].
Ask whether the product is semaglutide base or a semaglutide salt. FDA has warned about compounded products labeled as semaglutide sodium or semaglutide acetate, which are different active ingredients that have not been evaluated or approved; this has been associated with safety and quality concerns [4].
Confirm the device or dosage form. FDA has alerted clinicians and patients to dosing errors with compounded injectable semaglutide, including confusion from multi‑dose vials with different concentrations or units not aligned with FDA‑approved pens [3].
If the product is compounded, ask whether it is prepared by a state‑licensed 503A pharmacy for an individual prescription or by a registered 503B outsourcing facility for office use. FDA’s compounding framework distinguishes 503A and 503B operations and ties their activities to specific federal requirements, especially when supply normalizes [1].
Ask the pharmacy to explain why compounding is being used now and how current availability of FDA‑approved products factors into that decision, given FDA’s policies as GLP‑1 supply stabilizes [1].
Request written information that accompanies the product. FDA‑approved semaglutide includes an FDA Medication Guide and labeling with standardized safety information; compounded products may have different or limited instructions, which contributes to dosing errors and safety risks reported by FDA [3, 8].

Pharmacy legitimacy checks in Atlanta: Questions to ask

Patients in Atlanta often want practical steps to assess pharmacy legitimacy without relying on unverifiable online claims. The prompts below help you gather objective details you can review with your prescribing clinician before deciding where to fill a prescription. These are not instructions to make medication changes without your prescriber.

What is your Georgia pharmacy license number and physical dispensing address?
Are you a traditional 503A pharmacy dispensing per individual prescription, or a 503B outsourcing facility supplying office‑use products to clinics? Please state which applies for this product [1].
If compounded, who performs the compounding? If a 503B outsourcing facility is involved, which one [1]?
Will the dispensed label specify semaglutide base (not a salt form), the concentration per mL, and clear units that match the accompanying dosing instructions to minimize confusion [3, 4]?
Do you dispense an FDA‑approved semaglutide brand when it is prescribed? If not, why not, given FDA’s position and supply updates [1, 4]?
What documentation will I receive with the medication? For FDA‑approved products, an FDA Medication Guide is required; please confirm it will be included [8].
Can you provide the lot number and expiration/beyond‑use date on request, and who should I contact promptly if the labeling or instructions differ from what my clinician reviewed with me [3]?

Storage, handling, and injection education: What to confirm

Whether your prescription is an FDA‑approved product or a compounded alternative, confirm where to find official storage, handling, and device instructions and how you will learn correct use. FDA‑approved semaglutide labeling includes guidance on storage, preparation, missed doses, and important warnings; review these materials with your prescribing clinician and do not change how you use the medication without their direction [8]. FDA has reported dosing errors with compounded semaglutide when vials, syringes, or instructions used different units or concentrations; clear training and written instructions help reduce these risks [3].

Follow‑up and monitoring topics to clarify before starting

Guidelines recommend that pharmacotherapy for obesity be prescribed and monitored by clinicians and integrated with nutrition, physical activity, sleep, and cardiometabolic risk management. Ask your supervising physician about the following before you begin. Do not adjust any medications without the prescribing clinician [2, 6, 7].

Your goals and how progress will be measured beyond the scale, such as appetite patterns, meal tolerance, physical function, and cardiometabolic markers, consistent with guideline‑based obesity care [2, 6, 7].
Which potential adverse effects to watch for and how to report them promptly. FDA‑approved semaglutide labeling describes gastrointestinal effects like nausea, vomiting, and diarrhea; possible gallbladder events; pancreatitis; potential hypoglycemia when used with certain other medicines; and other warnings. Review these with your clinician and the Medication Guide [8].
Personal history or risk factors that may influence GLP‑1 use, including plans for pregnancy, past pancreatitis, gallbladder disease, or other conditions referenced in the Medication Guide. Discuss how these considerations shape monitoring without making changes on your own [8].
How injection technique training will be provided; where to find official device instructions; storage during daily life or travel; and what to do if a dose is delayed or missed per FDA‑approved labeling, with clinician guidance [8].
How your current medications will be reviewed for interactions or overlapping effects, and when to contact the clinic if appetite suppression, dehydration risk, or glycemia concerns arise. Do not change medications unless guided by the prescribing clinician [2, 6, 8].
What to do if you receive a product with labeling that differs from what you were taught (for example, a multi‑dose vial with unfamiliar units). Clarify who to call first to prevent dosing errors, which FDA has reported with compounded products [3].

When you might encounter compounded semaglutide in 2026

You may hear about compounded semaglutide if an FDA‑approved product is difficult to obtain, if a clinic uses office‑stock from an outsourcing facility, or if a pharmacy markets compounded versions. FDA has clarified that as national supply stabilizes, compounding policies narrow and compounders must align with federal requirements; patients can ask pharmacies and clinics to explain how current availability affects their product sourcing [1]. FDA has also summarized safety concerns with unapproved GLP‑1 products, including variable potency and labeling differences, and has issued alerts about dosing errors reported with compounded injectable semaglutide [3, 4]. These points support a cautious, verification‑first approach.

Local context: GLP‑1 consultations at Atlanta Medical Institute

Atlanta Medical Institute offers weight management services and consultations about semaglutide as part of its programs. If you are comparing options in Atlanta, it can be useful to bring the verification and monitoring questions from this article to your visit and review them with your clinician [9].

A practical checklist you can bring to your appointment or pharmacy

What exact product will be dispensed: the FDA‑approved brand with a Medication Guide, or a compounded preparation [8]?
If compounded, is it prepared by a 503A pharmacy for an individual prescription or by a 503B outsourcing facility for office use, and why now given FDA’s policy updates as supply stabilizes [1]?
Does the label say semaglutide base (not sodium or acetate) and list a clear concentration and units to reduce dosing confusion [3, 4]?
What education will I receive on storage, device setup, missed doses, and safety warnings, and where is this documented in FDA‑approved labeling for reference [8]?
Who should I contact promptly if I experience potential adverse effects or receive a product that looks different from training materials, given FDA alerts about dosing errors with compounded vials [3]?

Limitations and uncertainty to keep in mind

Availability, pricing, and product sourcing can change as manufacturers scale supply or update distribution. Federal guidance on compounding has evolved with shortage status, and individual pharmacies may change their practices accordingly [1]. Safety information for FDA‑approved semaglutide is updated through official labeling; reviewing the most current Medication Guide with your clinician helps ensure decisions reflect the latest information [8]. FDA and the American Diabetes Association advise prioritizing FDA‑approved options when feasible and exercising caution with compounded alternatives [4, 5].

Is compounded semaglutide the same as an FDA‑approved semaglutide product?

No. Compounded semaglutide is not FDA‑approved and may differ in potency, concentration, ingredients, or labeling. FDA has raised safety and quality concerns about unapproved GLP‑1 products and has reported dosing errors associated with compounded injectable semaglutide [4, 3].

My vial says “semaglutide sodium” or “acetate.” Does that matter?

Yes, it matters. FDA has warned about products labeled as semaglutide sodium or semaglutide acetate; these are different active ingredients than semaglutide base and have not been evaluated or approved as substitutes. Patients and clinicians should be aware of this distinction when reviewing labels [4].

Do ongoing drug shortages still justify compounded semaglutide in 2026?

FDA clarified compounding policies as national GLP‑1 supply stabilizes. As availability improves, federal allowances for making copies narrow, and compounders are expected to comply with 503A/503B requirements accordingly. Patients can ask pharmacies to explain how current availability affects their approach [1].

What follow‑up and safety topics should I cover before starting semaglutide?

Ask about the FDA Medication Guide, injection technique training, storage and handling, what to do for delayed or missed doses per labeling, potential adverse effects and when to report them, and how progress will be monitored within a comprehensive program. Do not change medications without the prescribing clinician [8, 2, 6].

Where can I find reliable safety information about semaglutide?

FDA‑approved semaglutide labeling includes key warnings and precautions, including gastrointestinal effects, pancreatitis, gallbladder events, and other risks. Review these with your clinician and the official Medication Guide rather than relying on informal instructions [8].

Sources

When to Talk With a Clinician

Contact Atlanta Medical Institute to discuss your goals, health history, and appropriate options with a qualified clinician.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Medication and hormone-treatment eligibility, risks, monitoring, and results vary; consult a qualified healthcare professional.